Gerontechnology Evaluation Framework: Outcome Validation
Launched by THE UNIVERSITY OF HONG KONG · Nov 17, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Gerontechnology Evaluation Framework: Outcome Validation, is focused on understanding how important certain evaluation indicators are when it comes to technology designed for older adults. The goal is to gather feedback from different groups of people to see how well these indicators apply in real-life situations. Participants will be asked to fill out a questionnaire where they will share their thoughts on the importance of these evaluation indicators.
To be eligible for this study, participants should be either elderly individuals aged 60 and above, caregivers for elderly individuals or those with disabilities, staff who work in social services for the elderly or disabled, or people involved in companies that create or sell technology for older adults. However, those who cannot read or write in Chinese will not be able to participate. While the trial is not yet recruiting, those who qualify can expect to contribute valuable insights that could help improve technology for older adults.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • People in one of these categories: Working or has worked in a social service setting for the elderly or person with disability (Staff), an elderly aged 60 or above (User), a person with physical or disability (User), an informal caregiver for an elderly or a person with disability (Caregiver), or belonging to a company/or that has developed or retailed gerontechnology products (Supplier)
- Exclusion Criteria:
- • Unable to read or write in Chinese
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported